{"id":177391,"date":"2011-05-24T00:00:00","date_gmt":"2011-05-23T22:00:00","guid":{"rendered":"https:\/\/hwpd.bcfi-cbip.be\/lagence-europeenne-des-medicaments-recommande-la-suspension-des-specialites-a-base-de-buflomedil-a-usage-oral-en-belgique-loftyl\/"},"modified":"2026-04-13T11:34:26","modified_gmt":"2026-04-13T09:34:26","slug":"lagence-europeenne-des-medicaments-recommande-la-suspension-des-specialites-a-base-de-buflomedil-a-usage-oral-en-belgique-loftyl","status":"publish","type":"post","link":"https:\/\/www.bcfi-cbip.be\/fr\/lagence-europeenne-des-medicaments-recommande-la-suspension-des-specialites-a-base-de-buflomedil-a-usage-oral-en-belgique-loftyl\/","title":{"rendered":"L\u2019Agence europ\u00e9enne des m\u00e9dicaments recommande la suspension des sp\u00e9cialit\u00e9s \u00e0 base de buflom\u00e9dil \u00e0 usage oral (en Belgique: Loftyl\u00ae)"},"content":{"rendered":"<div class='tekst'>\n<p><span style='font-family:arial'>Le Comit\u00e9 des m\u00e9dicaments \u00e0 usage humain (<em>Committee for Medicinal Products for Human Use&#x002C;<\/em> CHMP) de l\u2019Agence europ\u00e9enne des m\u00e9dicaments (<em>European Medicines Agency<\/em>&#x002C; EMA) recommande la suspension des sp\u00e9cialit\u00e9s \u00e0 base de buflom\u00e9dil \u00e0 usage oral (en Belgique: Loftyl\u00ae) et conseille aux m\u00e9decins de ne plus les prescrire: voir communiqu\u00e9 du 20 avril sur le site de l\u2019EMA. <\/span><span style='font-family:arial'><a href='http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2011\/05\/news_detail_001260.jsp&#038;murl=menus\/news_and_events\/news_and_events.jsp&#038;mid=WC0b01ac058004d5c1'><span style='color:windowtext'>www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2011\/05\/news_detail_001260.jsp&#038;murl=menus\/news_and_events\/news_and_events.jsp&#038;mid=WC0b01ac058004d5c1<\/span><\/a><\/span><\/p>\n<p><span style='font-family:arial'>L\u2019EMA a entam\u00e9 une \u00e9valuation du rapport b\u00e9n\u00e9fices\/risques du buflom\u00e9dil suite \u00e0 la d\u00e9cision prise en f\u00e9vrier 2011 par les autorit\u00e9s fran\u00e7aises de retirer du march\u00e9 les sp\u00e9cialit\u00e9s \u00e0 base de buflom\u00e9dil. En effet&#x002C; malgr\u00e9 les mesures prises en 2007 pour limiter les risques (entre autres retrait des pr\u00e9parations fortement dos\u00e9es&#x002C; voir aussi Folia de f\u00e9vrier 2007 et d\u2019ao\u00fbt 2007)&#x002C; de nouveaux cas d\u2019effets ind\u00e9sirables cardiaques et neurologiques sont encore toujours rapport\u00e9s avec le buflom\u00e9dil. En raison de ces effets ind\u00e9sirables graves et des doutes quant \u00e0 l\u2019efficacit\u00e9 du buflom\u00e9dil&#x002C; le CHMP recommande la suspension des sp\u00e9cialit\u00e9s \u00e0 base de buflom\u00e9dil \u00e0 usage oral. Le CHMP donnera un avis d\u00e9finitif d\u00e8s que l\u2019\u00e9valuation des formes parent\u00e9rales de buflom\u00e9dil sera achev\u00e9e ( les formes parent\u00e9rales de buflom\u00e9dil ne sont pas disponibles en Belgique). <\/span><\/p>\n<p><span style='font-family:arial'>Loftyl\u00ae a d\u00e8s lors \u00e9t\u00e9 retir\u00e9 du march\u00e9 en Belgique (situation au 26\/05\/11).<\/span><\/p>\n<p>\u00a0<\/p>\n<p>\u00a0<\/p>\n<p>\u00a0<\/p>\n<p>\u00a0<\/p>\n<p>\u00a0<\/p>\n<p>\u00a0<\/p>\n<p>\u00a0<\/p>\n<p>\u00a0<\/p>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Le Comit\u00e9 des m\u00e9dicaments \u00e0 usage humain (Committee for Medicinal  [&#8230;]<\/p>\n","protected":false},"author":9,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[12,52],"tags":[20213,20224],"class_list":["post-177391","post","type-post","status-publish","format-standard","hentry","category-actualites","category-2011-fr","tag-import_tags","tag-import_tags-nl"],"_links":{"self":[{"href":"https:\/\/www.bcfi-cbip.be\/fr\/wp-json\/wp\/v2\/posts\/177391","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.bcfi-cbip.be\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bcfi-cbip.be\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bcfi-cbip.be\/fr\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bcfi-cbip.be\/fr\/wp-json\/wp\/v2\/comments?post=177391"}],"version-history":[{"count":1,"href":"https:\/\/www.bcfi-cbip.be\/fr\/wp-json\/wp\/v2\/posts\/177391\/revisions"}],"predecessor-version":[{"id":179965,"href":"https:\/\/www.bcfi-cbip.be\/fr\/wp-json\/wp\/v2\/posts\/177391\/revisions\/179965"}],"wp:attachment":[{"href":"https:\/\/www.bcfi-cbip.be\/fr\/wp-json\/wp\/v2\/media?parent=177391"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bcfi-cbip.be\/fr\/wp-json\/wp\/v2\/categories?post=177391"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bcfi-cbip.be\/fr\/wp-json\/wp\/v2\/tags?post=177391"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}